Advisory Panel Votes for Emergency FDA Approval of Moderna’s COVID-19 Vaccine

December 18, 2020

Yesterdaythe Vaccines and Related Biological Products Advisory Committee, made up of nongovernmental scientists and public health experts from across the United States, voted to recommend that the U.S. Food and Drug Administration (FDA) grant emergency use authorization (EUA) for Moderna’s COVID-19 vaccine.   

Last week this same advisory panel recommended that the FDA approve the Pfizer-BioNTech COVID-19 vaccine for emergency use, which the FDA did one day later on December 11. 

Here’s a look at how the Moderna and Pfizer-BioNTech vaccines compare

IMPORTANT TO NOTE: COVID-19 vaccine products must not be mixed and matched.

Pfizer and BioNTech Covid-19 vaccine:

  • 95% effective in 44,000 trial participants
  • 2 doses; 3 weeks apart
  • Storage: must be transported and kept at minus 70C

Moderna Covid-19 vaccine:

  • 94.1% effective in 30,000 trial participants
  • 2 doses; 4 weeks apart
  • Storage: can survive for six months at minus 20C, the temperature of a standard domestic freezer

If you have questions, please contact the ISMS Health Policy Research and Advocacy team by email

Share this article:

Cookie Consent

Cookies are required for some functionality on our site. View our privacy policy for more information.